Integrating Biomarkers and Imaging for Cardiovascular Disease Risk Assessment in Diabetes

[1]  T. Ivanova,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice , 2016 .

[2]  J. Boer,et al.  Novel Biomarkers to Improve the Prediction of Cardiovascular Event Risk in Type 2 Diabetes Mellitus , 2016, Journal of the American Heart Association.

[3]  M. Jørgensen,et al.  Prediction of First Cardiovascular Disease Event in Type 1 Diabetes Mellitus: The Steno Type 1 Risk Engine , 2016, Circulation.

[4]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[5]  Mark D. Huffman,et al.  AHA Statistical Update Heart Disease and Stroke Statistics — 2012 Update A Report From the American Heart Association WRITING GROUP MEMBERS , 2010 .

[6]  H. May,et al.  Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. , 2014, JAMA.

[7]  R. Hayward,et al.  Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. , 2014, JAMA internal medicine.

[8]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[9]  Mark Woodward,et al.  The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes , 2013, Diabetes Care.

[10]  M. Kashani,et al.  Improving Assessment of Cardiovascular Disease Risk by Using Family History: An Integrative Literature Review , 2013, The Journal of cardiovascular nursing.

[11]  L. Tarantini,et al.  Cardiovascular Biomarkers, Cardiac Dysfunction, and Outcomes in Patients With Type 2 Diabetes: A Prospective, Multicenter Study , 2013, Diabetes Care.

[12]  Mohamed M. Ali,et al.  Prevalence and Predictors of Ischemia and Outcomes in Outpatient Diabetic Patients Referred for SPECT Myocardial Perfusion Imaging , 2013 .

[13]  Mohamed M. Ali,et al.  Prevalence and Predictors of Ischemia and Outcomes in Outpatients With Diabetes Mellitus Referred for Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging , 2013, Circulation. Cardiovascular imaging.

[14]  B. Zinman,et al.  Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: systematic review and meta-analysis , 2013, British medical journal.

[15]  M. Budoff,et al.  Impact of coronary artery calcium progression and statin therapy on clinical outcome in subjects with and without diabetes mellitus. , 2013, The American journal of cardiology.

[16]  V. Gudnason,et al.  N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS , 2012, European heart journal.

[17]  R. Blankstein,et al.  Association Between Coronary Vascular Dysfunction and Cardiac Mortality in Patients With and Without Diabetes Mellitus , 2012, Circulation.

[18]  D. Goff,et al.  Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. , 2012, JAMA.

[19]  Robert Dufour,et al.  Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial , 2012, The Lancet.

[20]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[21]  T. Kawasaki,et al.  Usefulness of sum of the thickness of plaque in the carotid artery for predicting the presence and the extent of the coronary artery disease in patients with type 2 diabetes mellitus without known coronary artery disease. , 2012, Diabetes research and clinical practice.

[22]  R. Kronmal,et al.  Metabolic Syndrome, Diabetes, and Incidence and Progression of Coronary Calcium , 2012 .

[23]  R. Kawamori,et al.  Combination of the Framingham Risk Score and Carotid Intima-Media Thickness Improves the Prediction of Cardiovascular Events in Patients With Type 2 Diabetes , 2011, Diabetes Care.

[24]  M. Pencina,et al.  Improved Cardiac Risk Assessment With Noninvasive Measures of Coronary Flow Reserve , 2011, Circulation.

[25]  S. Gudbjörnsdottir,et al.  A new model for 5‐year risk of cardiovascular disease in Type 1 diabetes; from the Swedish National Diabetes Register (NDR) , 2011, Diabetic medicine : a journal of the British Diabetic Association.

[26]  M. Budoff,et al.  Impact of Subclinical Atherosclerosis on Cardiovascular Disease Events in Individuals With Metabolic Syndrome and Diabetes , 2011, Diabetes Care.

[27]  N. Cook,et al.  Sensitive Cardiac Troponin T Assay and the Risk of Incident Cardiovascular Disease in Women With and Without Diabetes Mellitus: The Women's Health Study , 2011, Circulation.

[28]  Eric Boerwinkle,et al.  Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study , 2011, Circulation.

[29]  Zahi A Fayad,et al.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2010, Circulation.

[30]  M. Woodward,et al.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.

[31]  P. Greenland,et al.  Coronary artery calcium score and risk classification for coronary heart disease prediction. , 2010, JAMA.

[32]  Eric Boerwinkle,et al.  Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. , 2010, Journal of the American College of Cardiology.

[33]  A. Jaffe,et al.  Analytical validation of a high-sensitivity cardiac troponin T assay. , 2010, Clinical chemistry.

[34]  J. Danesh,et al.  C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis , 2010, The Lancet.

[35]  A. Meta-analysis.  Ankle Brachial Index Combined With Framingham Risk Score to Predict Cardiovascular Events and Mortality , 2010 .

[36]  D. Lloyd‐Jones,et al.  Systematic Examination of the Updated Framingham Heart Study General Cardiovascular Risk Profile , 2009, Circulation.

[37]  E. Barrett,et al.  Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. , 2009, JAMA.

[38]  I. Idris,et al.  Is diabetes a coronary risk equivalent? Systematic review and meta‐analysis , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[39]  S. Humphries,et al.  Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. , 2008, European heart journal.

[40]  A Hofman,et al.  Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. , 2008, JAMA.

[41]  Moyses Szklo,et al.  Coronary calcium as a predictor of coronary events in four racial or ethnic groups. , 2008, The New England journal of medicine.

[42]  R Peto,et al.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[43]  Gretchen A. Piatt,et al.  Deficiencies of Cardiovascular Risk Prediction Models for Type 1 Diabetes A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. , 2006, Diabetes Care.

[44]  N. Wong,et al.  Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. , 2005, Diabetes care.

[45]  Daniel S Berman,et al.  Prognostic value of coronary artery calcium screening in subjects with and without diabetes. , 2004, Journal of the American College of Cardiology.

[46]  P. Macfarlane,et al.  Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study , 2003, Circulation.

[47]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[48]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[49]  R. D'Agostino,et al.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.